What is the prevalence of CYP2C19*2 and CYP2C19*3 allelic variants and their association with clopidogrel resistance in patients with cardiovascular disease in Trinidad & Tobago?
A high proportion of Trinidadian patients with cardiovascular disease carry the CYP2C19*2 loss-of-function allele, suggesting that genotype-guided antiplatelet therapy may be beneficial in this population.
INTRODUCTION: Trinidad ten homozygous and 30 heterozygous. Indian patients comprised 65% of the cohort and were four times more likely to carry the CYP2C19*2 allele than African patients. CONCLUSIONS: A large proportion of Trinidadian patients with CVD who are prescribed or may be prescribed clopidogrel carry genetic variants associated with clopidogrel resistance. These results emphasize the clinical need for further investigation into whether CYP2C19*2 genotype should guide clopidogrel use for the cardiovascular disease population in Trinidad & Tobago. A slide deck is available for this article.
Jones et al. (Mon,) studied this question.